Tariffs – Is IVD OK?
May 29, 2025
No Comments
Company Q1 Investor Calls: Most IVD companies have downplayed tariff impact. Small % of revenues affected. Most emphasizing the industry’s having the most advanced supply chains in global industry, one that can shift as tariff targets change. 2 Major Trade Associations: Tariffs are damaging and we need a medical exemption. IVD Industry Blogger:
In Vitro Diagnostics Stocks, 2025 Flu Season, Diasorin Reports
May 7, 2025
No Comments
How are IVD stocks doing in the general market fall? About that huge flu season. A mid-size player reports, which (can be) a measure of the growthiness of the market. And Roche adheres its blood test to its IT-IVD product to aid interpreting results. DiaSorin Reports – Overall Growth, China VP Concerns, Not
Clinical Laboratory Market Nears $400 Billion: Report
April 22, 2025
No Comments
The market for clinical lab services is $396 billion, per a report from our partner Howe Sound Global Clinical Medical Laboratory Services Market – Eye On IVD As the healthcare landscape continues to evolve, the In Vitro Diagnostic industry is poised for significant growth, driven by advancements in biotechnology, including Artificial Intelligence. Knowledge
“It Just Wreaks Havoc” – Webinar Debates Tariff Impact on IVD, LDT Rule Vacation, Other Topics
April 4, 2025
No Comments
Multiple topics were discussed at Wednesday’s State of The IVD Industry Webinar. Tariffs. NIH cuts. Proposed Medicaid changes. Agency shakeups. The FDA LDT ruled unlawful by a court. At the same time: new IVD products, emerging infectious threats, and breakthrough technologies hitting the market. Watch the webinar here:
We Cover IVD
Order the Most Comprehensive Report on AI in IVD
Finally: A Realistic Look at the Potential for AI in IVD. With Predictions, Analysis and Vetted Numbers.
